Tarceva (erlotinib) — United Healthcare
Kidney Cancer
Initial criteria
- Diagnosis of kidney cancer
- Disease is stage IV or relapsed
- Disease is of non-clear cell histology
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tarceva therapy
Approval duration
12 months